Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Grunwald

Showing results (71-80 of 124) with videos related to

Pageof 13
Sort By:
Blood Advances|October 25, 2019
Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemiaPaul Milne, Charlotte Wilhelm-Benartzi, Michael R Grunwald, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 1, 2019
Effect of CYP3A4, CYP3A5, and ABCB1 Polymorphisms on Intravenous Tacrolimus Exposure and Adverse Events in Adult Allogeneic Stem Cell Transplant PatientsIssam S Hamadeh, Qing Zhang, Nury Steuerwald, et al.
Blood|April 25, 2013
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutationFarhad Ravandi, Mona Lisa Alattar, Michael R Grunwald, et al.
British Journal of Haematology|July 13, 2021
Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease - a real-world outcomes analysisSameem Abedin, Nahid Rashid, Mark Schroeder, et al.
Leukemia Research|June 26, 2022
Outcomes and hospitalization patterns of patients with acute myelogenous leukemia treated with frontline CPX-351 or HMA/venetoclaxAleksander L Chojecki, Justin Arnall, Danielle Boselli, et al.
Blood Advances|February 12, 2021
Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donorsMichael R Grunwald, Mei-Jie Zhang, Hany Elmariah, et al.
Transplantation and Cellular Therapy|January 4, 2025
Donor Type Does Not Impact Late Graft Failure Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease ProphylaxisCindy Lynn Hickey, Mei-Jie Zhang, Mariam Allbee-Johnson, et al.
Transplantation and Cellular Therapy|November 14, 2021
Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial OutcomesPaul V O'Donnell, Claudio G Brunstein, Ephraim J Fuchs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2025
Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic TransplantationStephanie J Lee, Brent Logan, Mary M Horowitz, et al.
Haematologica|July 6, 2023
Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaborationTania Jain, Hua-Ling Tsai, Hany Elmariah, et al.
Pageof 13

Showing results (71-80 of 124) with videos related to

Sort By:
Pageof 13
Blood Advances|October 25, 2019
Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemiaPaul Milne, Charlotte Wilhelm-Benartzi, Michael R Grunwald, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 1, 2019
Effect of CYP3A4, CYP3A5, and ABCB1 Polymorphisms on Intravenous Tacrolimus Exposure and Adverse Events in Adult Allogeneic Stem Cell Transplant PatientsIssam S Hamadeh, Qing Zhang, Nury Steuerwald, et al.
Blood|April 25, 2013
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutationFarhad Ravandi, Mona Lisa Alattar, Michael R Grunwald, et al.
British Journal of Haematology|July 13, 2021
Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease - a real-world outcomes analysisSameem Abedin, Nahid Rashid, Mark Schroeder, et al.
Leukemia Research|June 26, 2022
Outcomes and hospitalization patterns of patients with acute myelogenous leukemia treated with frontline CPX-351 or HMA/venetoclaxAleksander L Chojecki, Justin Arnall, Danielle Boselli, et al.
Blood Advances|February 12, 2021
Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donorsMichael R Grunwald, Mei-Jie Zhang, Hany Elmariah, et al.
Transplantation and Cellular Therapy|January 4, 2025
Donor Type Does Not Impact Late Graft Failure Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease ProphylaxisCindy Lynn Hickey, Mei-Jie Zhang, Mariam Allbee-Johnson, et al.
Transplantation and Cellular Therapy|November 14, 2021
Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial OutcomesPaul V O'Donnell, Claudio G Brunstein, Ephraim J Fuchs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2025
Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic TransplantationStephanie J Lee, Brent Logan, Mary M Horowitz, et al.
Haematologica|July 6, 2023
Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaborationTania Jain, Hua-Ling Tsai, Hany Elmariah, et al.
Pageof 13